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Introduction
Pregnant women and neonates are two of the most vulnerable 
groups globally. Despite significant achievements in reducing 
preventable maternal, newborn, and child morbidity and mor-
tality, in line with the Sustainable Development Goals, further 
progress is still needed, especially in low- and middle-income 
countries (LMICs)1.
A systematic analysis for the Global Burden of Disease Study 
reports that respiratory infections and sepsis are among the lead-
ing causes of neonatal deaths in 195 countries across the world2. 
The development of new vaccines to enhance maternal immuni-
zation, e.g. for group B streptococcus and respiratory syncytial 
virus, have the potential to reduce serious morbidity and mortal-
ity in newborns. However, new vaccine development requires 
robust systems to collect and assess maternal, newborn, and child 
health (MNCH) outcomes, including safety information, fol-
lowing the use of novel vaccines, drugs, and biological products 
during pregnancy. Indeed, the US Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA) require 
extensive post-licensure safety monitoring commitments, particu-
larly active surveillance, from market authorization holders for 
health products that could be used during pregnancy3.
A recent analysis, funded by the Bill and Melinda Gates Founda-
tion4, reported that the majority of vaccine pharmacovigilance 
systems in LMICs consist of spontaneous (passive) adverse event 
reporting, where any health professional or patient, among other 
individuals, are able to report a suspected adverse event. In order 
to interpret the data, however, knowledge of the background rates 
of health outcomes of interest is needed, as well as data regard-
ing the number of individuals exposed to the vaccine. Map-
ping existing systems will facilitate the potential for countries 
to work and increase their ability to monitor the most important 
health outcomes following immunization5. Background population 
data on adverse pregnancy outcomes are also helpful for designing 
active vaccine safety surveillance studies at sentinel sites.
Surveillance systems have been established in certain LMICs for 
monitoring birth, deaths, and key health indicators. Addition-
ally, the field of vaccine pharmacovigilance has expanded, but it 
has limited application to maternal immunization vigilance in 
LMICs. Major challenges are the recording of data across differ-
ent health system levels using different tools and platforms, dif-
ferent definitions and classifications for maternal and neonatal 
outcomes, the need for standardized definitions and measure-
ment (e.g. gestational age), and the need for information about 
exposures, such as vaccines, disaggregation of data, and 
the applicability of standards to LMICs6.
The Global Alignment of Immunization Safety Assessment in 
pregnancy (GAIA) project proposed case definitions for key 
events in MNCH and piloted them in 24 sentinel sites across 
four World Health Organization (WHO) regions7. A feasibil-
ity assessment evaluated the ability of GAIA case definitions to 
identify and classify selected outcomes and/or maternal vaccina-
tion in LMICs. Additional field testing in LMICs of the GAIA 
definitions is ongoing, as there are continuing questions about 
their practicality, utility, and impacts on improving data quality8,9.
In high-income countries, MNCH outcomes are tracked through 
vital registration systems and data from medical records and 
other national health reporting systems. In LMICs, however, 
these data are generally not available, nor do they interface with 
pharmacovigilance platforms or initiatives. Births, deaths, and 
clinical events often occur outside of medical facilities; vital reg-
istration systems are not always comprehensive; and medical 
records are often incomplete, poorly maintained and paper-based, 
making it cumbersome to link these across systems. However, a 
number of surveys, surveillance systems, and health information 
systems are in place that could provide information on mater-
nal and infant health in low-resource settings. Thus, we intend 
to identify existing electronic and mixed paper-electronic 
systems that collect continuous maternal and neonatal data in 
LMICs, using a scoping review, with the potential to inform 
active safety electronic surveillance for novel vaccines using 
standardized definitions. Given the importance of improving 
maternal interventions vigilance, the scoping review will also 
identify active safety surveillance systems in LMICs as applied 
to MNCH.
Methods
A scoping review is considered to be the most suitable approach 
to achieve the broad aim of this study. In contrast to the tra-
ditional systematic literature reviews that aim to answer spe-
cific questions, scoping reviews produce a broad overview of 
the field10,11. Scoping reviews may be undertaken to examine 
the extent, range, and nature of activities in a particular area, to 
summarize and disseminate findings, and to identify gaps in the 
existing body of knowledge. In addition to searching the pub-
lished literature in the main biomedical databases, grey literature 
is also explored, since it is very likely that most information (i.e. 
descriptions of systems that collect continuous perinatal data, 
pregnancy registries, etc.) may be found in government agency 
and non-governmental organization websites, international organi-
zations, such as the WHO, countries’ official Ministry of Health 
reports and technical guidance or regulatory documents, and 
meeting proceedings, among others.
Drafting and reporting of the scoping review will be guided 
by the Preferred Reporting Items for Systematic reviews and 
Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) 
Checklist12. This scoping review will use the methodological 
framework proposed by Arksey and O’Malley10, as well as the 
amendments made to this framework by Levac et al.13 and by the 
Joanna Briggs Institute14. The framework consists of six consecu-
tive stages: 1) identifying the research question; 2) identifying 
relevant studies; 3) study selection; 4) data extraction; 5) collat-
ing, summarizing, and reporting results; and 6) consultation. Each 
stage is briefly discussed below.
Stage 1: Identifying the research question
Arksey and O’Malley10 suggest an iterative process for devel-
oping one or more research questions. In the first stage, two 
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research questions for this scoping review have been identified 
based on gaps in the literature: 
• What existing prenatal and postnatal data collection 
systems are in place at the facility level and community 
level that could provide continuous, longitudinal, 
and individual information on maternal and neonatal 
health outcomes in LMICs?
• Do existing prenatal and postnatal data collection 
systems have the capacity to inform active safety 
surveillance for maternal vaccines and other maternal 
health interventions?
Stage 2: Identifying Relevant Studies
A comprehensive search strategy will be developed in order to 
identify relevant literature from 2014 or the year of database 
inception to August 2019, underpinned by key inclusion criteria. 
These are based on the ‘Population–Concept–Context’ frame-
work recommended by the Joanna Briggs Institute for scoping 
reviews14, which has roots in the PICO (population, interven-
tion, comparator, and outcome) framework commonly used to 
focus clinical questions and develop systematic literature search 
strategies.
Population–Concept–Context. P—Population = Pregnant women 
and neonates.
C—Concept = Articles with a specific focus on existing elec-
tronic and paper-electronic systems, in LMICs that collect con-
tinuous, prospective, and individual-level data from antenatal 
care, delivery, postpartum (up to 42 days), and neonatal care (up 
to 28 days) at the facility or/and community level, at the national 
and/or district level, and/or at large hospitals.
From the identified systems, we will record information on 
the following data points: 
a) The country/-ies of operation.
b) The extent of the registry data collection (in facilities 
only, in community services only, both, or not defined).
c) The primary purpose of the system, such as clinical 
care information systems, mortality registries, insurance 
registries, birth registration, other.
d) Records linkage, such as the use of unique, individual 
identifiers that allow for tracking mother-newborn-child 
across records and time.
e) The scale of the implementation of the registry 
(national, district, local, or not defined).
f) The specified population captured by the registry data 
collection (total population, only subgroups/select 
population, or not defined).
g) The data collection method used (paper, electronic, 
both, or not defined).
h) Whether the primary data were collected and entered 
directly into the registry, or if the registry was 
based on a secondary/duplicate data collection from 
existing sources (direct, duplicated, or not defined).
i) Health care periods that the system registers (antena-
tal care, delivery, neonatal, postnatal care, until facility 
discharge)
j) Whether it collects pregnancy and neonatal outcomes 
defined by the GAIA project (Extended data)
k) Whether it collects maternal sociodemographic variables 
(age, education, etc.), obstetric characteristics (gesta-
tion, parity, etc.), pre-existent conditions (HIV, syphilis, 
other), and process of ANC (number of visits, gesta-
tional age at first visit, preventive interventions, vaccine 
administration, etc.)
l) Type of terminology used (MedDRA, SNOMED, ICD10, 
other, not defined)
m) Who, where, and how individual data are captured
n) Baseline data (pregnancy and outcomes) timeframe
o) Capacity to compile and transfer electronic data
p) Whether it uses a mechanism/process(es) to link mater-
nal and neonatal health records, laboratory registry, 
medications, vaccines, other exposures of relevance, 
and to pool and link to other different data sources (vital 
statistics, etc.); if yes, description of the mechanism/ 
process
q) Whether and how data are monitored for quality; 
if yes, description of the mechanism/process(es)
r) Data repositories and back-up policy.
s) Whether data collection tools and system documentation 
are available
t) How maintenance and updates are performed
u) Data access, data extraction, and the ability to import 
and export data
v) Infrastructure status and whether the privacy protection 
is internal and external
w) Sponsor/funding
x) If the system had been used previously for active sur-
veillance or pharmacovigilance or post-marketing 
surveillance; if yes, what type of post-marketing sur-
veillance used (active vs passive, general vaccines vs 
maternal vaccines, surveillance of drugs, vaccines, other 
interventions)
C—Context = The review will include all study designs 
(e.g., randomized controlled trials, non-randomized comparative, 
pre-post, survey/cross-sectional, case-control, cohort, qualitative, 
case studies) and will not have language restrictions.
Inclusion criteria.
- Electronic or paper – electronic registries.
- LMICs (Extended data).
- Maternal and Neonatal Information Systems that 
continuously collect perinatal outcomes during antenatal 
care, delivery care, childbirth, and neonatal periods.
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- Existing system and used in the past 5 years.
- Demonstrated ability to collect prospective, longitudinal, 
and individual-level data.
- Active surveillance of maternal interventions, including 
pregnancy exposure registries and other types of 
active surveillance, including sentinel site active 
surveillance of maternal interventions.
Exclusion criteria.
- Paper-based only.
Search strategy. The search strategies, including search terms, 
will be initially drafted by the investigator team, then by an 
experienced librarian; it will be further refined through the 
team’s review and discussion.
We will run an initial search in MEDLINE. Subsequently, 
the following databases will be searched: EMBASE, Glo-
bal Health-OVID, Cochrane, LILACS (BVS-iAH-EN), Index 
Africanus, Bibliography of Asian Studies (BAS), Index Medi-
cus for the Eastern Mediterranean Region, Index Medicus 
for the South-East Asian Region, IndMed, KoreaMed, Cumula-
tive Index to Nursing and Allied Health Literature (CINAHL), 
Educational Resources Information Center, PsycINFO, Scopus 
and Web of Science (Extended data).
In the third and last step, reference lists of included studies, 
as well as websites of journals that display a strong interest in 
perinatal health information systems, as evidenced by numer-
ous publications on the topic, will be hand-searched using key-
words related to continuous perinatal health information systems, 
as outlined in the MEDLINE strategy to identify any additional 
literature.
The search strategy for grey literature will include searching 
in websites of existing Health Information Systems (HIS) (i.e., 
Sistema Informatico Perinatal (SIP), Global Network, DHIS2, 
INDEPTH, MRC and Wellcome Trust networks, Pasteur net-
works, etc.). We will also conduct searches of organizations that 
offer resources to evaluate HIS (Measure Evaluation, WHO/PAHO 
web, CARPHA, etc.), Ministries of Health of LMICs websites, 
and the Global Alignment of Immunization Safety Assessment in 
pregnancy website. We will contact authors to identify additional 
sources and contact experts to identify unpublished infor-
mation on relevant data collection systems. Also, a custom 
Google search will be performed using key words, translating 
the search strategy developed for literature databases. Finally, 
we will explore grey literature databases like OpenGray and 
SIGLE, MNCH meetings and websites of large MNCH projects, 
e.g., http://www.mcsprogram.org.
The literature search strategy will be reported in a manner that 
allows easy replication by others and will be presented in its 
entirety in the text, a table, and/or an appendix. The final refer-
ence lists of the articles included will be hand-searched for addi-
tional information. If data or data subsets of the same population 
were published in more than one article, we will select only the 
publication with the largest sample size, as appropriate.
Stage 3: Study selection
Following the execution of the search strategy, the identified 
records (titles and abstracts) will be collected in a reference 
manager for de-duplication and then uploaded into Cochrane’s 
COVIDENCE online software to manage the initial phases of 
scoping review and overviews. This software also enables inde-
pendent screening and logs disagreements and consensuses 
among reviewers.
According to the eligibility criteria mentioned above, the stud-
ies’ selection processes will be implemented over two stages. The 
first stage will involve the screening of each title and abstract in 
COVIDENCE by at least two independent reviewers to deter-
mine its eligibility for full-text screening. Each article will 
be categorized into one of three categories (Yes, Maybe, No) 
to assess the relevance and probability of full text retrieval.
In the second stage, all articles except those categorized as 
“No” (excluded) will be retrieved in full text for further analy-
sis. Disagreements between reviewers will be resolved by 
consensus of the whole team.
An adapted version of the PRISMA flow diagram will be 
used to report final numbers in the resulting study publica-
tion once the review is completed. Reasons for exclusion will 
be recorded at the full-text review stage.
Stage 4: Data extraction
A form for data extraction will be developed at the protocol 
stage to extract and sort key pieces of information from the 
selected full text articles. It will be pilot-tested and refined dur-
ing the full-text screening stage in order to capture more detailed 
information. Additional categories that may emerge during data 
extraction will be added accordingly. Data extraction will be done 
using Google documents’ online spreadsheets. A framework to 
assess and describe the existing MNCH health systems will be 
created based on some frameworks available in the literature.
Stage 5: Collating, summarizing, and reporting the results
In order to create a useful summary of the data, we will combine 
all Perinatal Health Information Systems and their characteristics 
from all sources into table(s) as appropriate.
A checklist for reporting scoping reviews, the ‘Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis: extension 
for Scoping Reviews (PRISMA-ScR),” will be used (Reporting 
guidelines).
Data will be organized in a database to create an Evidence and 
Gap map that will provide a visual overview of the geographical 
distribution of systems reviewed. The map will identify evidence 
gaps by comparing the key research questions identified with 
the available literature. It will be presented as an interactive geo-
graphical map and table(s). Analysis will be stratified by Global 
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Alliance for Vaccines and Immunization (GAVI) country so that 
the results will be stratified by GAVI versus non-GAVI LMICs.
Active surveillance vaccine studies and systems in pregnancy 
that use MNCH systems that are compliant with the eligibility 
criteria of this scoping review will be listed as relevant literature 
to discuss further.
Stage 6: Consultation
We will organize an Advisory Group meeting in Year 1 in New 
Orleans, Louisiana, USA, to discuss the results of the scop-
ing review, seek additional expert input, and select up to three 
systems to be further explored in situ.
We will present a final list of existing MNCH systems that were 
considered to help companies/researchers/regulators under-
stand where to access and abstract population-based back-
ground pregnancy outcomes data. This will aid in informing the 
denominator of active vaccine safety surveillance studies that 
are flexible enough to be updated, if necessary, to detect, assess, 
and respond to safety concerns derived from the introduction 
of novel maternal vaccines.
Based on scoping review results, Advisory Board members will 
review the information technology platforms from selected exist-
ing MNCH systems, especially core pregnancy outcome vari-
ables used across the systems, data quality control provisions, 
their ability to export data, how they are characterized, whether 
they easily could integrate with minimum requirements for 
active vaccine safety surveillance to help define the denominator 
of clinical and case-control or cohort surveillance studies indi-
cator rates, and their compliance with Good Clinical Practice, 
as appropriate.
Dissemination
Results of this scoping review will be published in a peer-
reviewed journal and presented at conferences, as appropri-
ate. All publications will be submitted to open access journals, 
and the databases, tools, and other materials generated by this 
project will be made publicly available.
Study status
The scoping review is in progress. Stage 1 to 4 are completed.
Data availability
Underlying data
No data is associated with this article.
Extended Data
Open Science Framework: Maternal and neonatal data collec-
tion systems in low- and middle-income countries: scoping 
review protocol, https://doi.org/10.17605/OSF.IO/W53JR15.
This project contains the following extended data: 
- Definitions of relevant terms
- List of LMICs and GAVI Countries
- Search Strategy
- GAIA project outcomes
Reporting guidelines
Open Science Framework: PRISMA-ScR checklist for ‘Maternal 
and neonatal data collection systems in low- and middle-income 
countries: scoping review protocol’, https://doi.org/10.17605/ 
OSF.IO/W53JR15.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Acknowledgments
The authors would like to thank Andrea Meyer for English editing.
Scoping Review Collaboration Group: Advisory Board group 
and Observers (Judith Absalon, MD, MPH; Steve Anderson, 
PhD, MPP; Fernando Althabe, MD; Shabir Madhi, MBBCh, 
FCPaeds, PhD; Elizabeth McClure, PhD; Flor M. Munoz, MD, 
MSc; Kissa W. Mwamwitwa, Mpharm; Annettee Nakimuli, 
MD, MMed Obs&gyn, PhD; Jennifer Clark Nelson, PhD; Lisa 
Noguchi, PhD, CNM; Lakshmi Panagiotakopoulos, MD, MPH; 
Esperanca Sevene, MD, MSc, PhD; Ajoke Sobanjo-ter Meu-
len MD, MSc; Patrick Zuber, MD); Institute for Clinical Effec-
tiveness and Health Policy (IECS) Collaborators group (Maria 
Belizan, MSC; Eduardo Bergel, PhD; Federico Rodriguez Cairoli, 
MD; Fabricio Castellanos, MD; Alvaro Ciganda, BSCS; Daniel 
Comande, BSc; Veronica Pingray, MPH).
References
1. Sobanjo-Ter Meulen A, Munoz FM, Kaslow DC, et al.: Maternal interventions 
vigilance harmonization in low- and middle-income countries: Stakeholder 
meeting report; Amsterdam, May 1-2, 2018. Vaccine. 2019; 37(20): 2643–50. 
PubMed Abstract | Publisher Full Text | Free Full Text 
2. GBD 2016 Lower Respiratory Infections Collaborators: Estimates of the global, 
regional, and national morbidity, mortality, and aetiologies of lower respiratory 
infections in 195 countries, 1990-2016: a systematic analysis for the Global 
Burden of Disease Study 2016. Lancet Infect Dis. 2018; 18(11): 1191–1210. 
PubMed Abstract | Publisher Full Text | Free Full Text 
3. U.S. Department of Health and Human Services Food and Drug Administration, 
Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation 
and Research (CBER), et al.: Postapproval Pregnancy Safety Studies Guidance 
for Industry Postapproval Pregnancy Safety Studies Guidance for Industry. 
2019; 1–30. 
Reference Source
4. Lackritz EM, Stepanchak M: Maternal Immunization Safety Monitoring in Low- 
and Middle-Income Countries: A Roadmap for Program Development. Seattle, 
Washington: GAPPS. 2017. 
Reference Source
5. IGO: GWHOWESLCB-N-S: Stakeholders Meeting on Maternal Interventions 
Page 6 of 11
Gates Open Research 2020, 4:18 Last updated: 06 MAY 2020
Vigilance: Safety Monitoring and Surveillance in Vaccine and other Research 
Settings. Report of a meeting: World Health Organization. 2018. 
Reference Source
6. Zuber PLF, Moran AC, Chou D, et al.: Mapping the landscape of global 
programmes to evaluate health interventions in pregnancy: the need for 
harmonised approaches, standards and tools. BMJ Glob Health. 2018; 3(5): 
e001053. 
PubMed Abstract | Publisher Full Text | Free Full Text 
7. Kochhar S, Clarke E, Izu A, et al.: Immunization in pregnancy safety surveillance 
in low and middle-income countries- field performance and validation of novel 
case definitions. Vaccine. 2019; 37(22): 2967–2974. 
PubMed Abstract | Publisher Full Text 
8. Bonhoeffer J, Kochhar S, Hirschfeld S, et al.: Global alignment of immunization 
safety assessment in pregnancy - The GAIA project. Vaccine. 2016; 34(49): 
5993–7. 
PubMed Abstract | Publisher Full Text 
9. Stuurman AL, Riera M, Lamprianou S, et al.: Vaccine safety surveillance in 
pregnancy in low- and middle-income countries using GAIA case definitions: 
A feasibility assessment. Vaccine. 2018; 36(45): 6736–43. 
PubMed Abstract | Publisher Full Text 
10. Arksey H, O'Malley L: Scoping studies: towards a methodological framework. 
Int J Soc Res Methodol. 2005; 8(1): 19–32. 
Publisher Full Text 
11. Armstrong R, Hall BJ, Doyle J, et al.: Cochrane Update. ‘Scoping the scope’ of a 
cochrane review. J Public Health (Oxf). 2011; 33(1): 147–50. 
PubMed Abstract | Publisher Full Text 
12. Shamseer L, Moher D, Clarke M, et al.: Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015: elaboration and 
explanation. BMJ. (Clinical research ed). 2015; 350: g7647. 
PubMed Abstract | Publisher Full Text 
13. Levac D, Colquhoun H, O'Brien KK: Scoping studies: advancing the 
methodology. Implement Sci. 2010; 5: 69. 
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Joanna Briggs Institute: The Joanna Briggs Institute Reviewers’ Manual 2015. 
Methodol JBI Scoping Rev Joanna Briggs Inst JBI. 2015. 
Reference Source
15. Berrueta M: Maternal and neonatal data collection systems in low- and middle-
income countries: scoping review protocol. 2020. 
http://www.doi.org/10.17605/OSF.IO/W53JR
Page 7 of 11




   Current Peer Review Status:
Version 1
 04 May 2020Reviewer Report
https://doi.org/10.21956/gatesopenres.14271.r28775
© 2020 Jauregui Wurst B. This is an open access peer review report distributed under the terms of the Creative
, which permits unrestricted use, distribution, and reproduction in any medium, provided theCommons Attribution License
original work is properly cited.



















Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Page 8 of 11







I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
 04 May 2020Reviewer Report
https://doi.org/10.21956/gatesopenres.14271.r28774
































Page 9 of 11












Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly





I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
 14 April 2020Reviewer Report
https://doi.org/10.21956/gatesopenres.14271.r28726
© 2020 Kirby R. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.









Page 10 of 11
Gates Open Research 2020, 4:18 Last updated: 06 MAY 2020
Gates Open Research
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes




I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Page 11 of 11
Gates Open Research 2020, 4:18 Last updated: 06 MAY 2020
